Marc Goodman
Stock Analyst at Leerink Partners
(2.95)
# 1,409
Out of 5,113 analysts
94
Total ratings
58.67%
Success rate
29.35%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MPLT MapLight Therapeutics | Initiates: Outperform | $30 | $19.94 | +50.45% | 1 | Nov 21, 2025 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $5 | $1.34 | +273.13% | 1 | Nov 17, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Market Perform | $19 | $21.42 | -13.63% | 3 | Oct 23, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Outperform | $34 | $19.70 | +72.59% | 1 | Oct 6, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $50 | $11.13 | +349.24% | 7 | Aug 12, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $11.92 | -16.11% | 5 | May 7, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $147.00 | +2.04% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $4.15 | -75.90% | 3 | Dec 4, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $17.07 | +87.46% | 1 | Apr 15, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $154.54 | -83.82% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $16.77 | +198.15% | 1 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $7.18 | +178.55% | 3 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $100 → $115 | $141.84 | -18.92% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $169.91 | +82.45% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $43.23 | +6.41% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $26.60 | -21.05% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $166.00 | +26.51% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.95 | +238.98% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $27.81 | -2.91% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $5.01 | +199.40% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $594.01 | -54.55% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $222.82 | -56.92% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $53.33 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $100.69 | -33.46% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $13.31 | +636.29% | 7 | Oct 5, 2017 |
MapLight Therapeutics
Nov 21, 2025
Initiates: Outperform
Price Target: $30
Current: $19.94
Upside: +50.45%
Ovid Therapeutics
Nov 17, 2025
Initiates: Outperform
Price Target: $5
Current: $1.34
Upside: +273.13%
Avadel Pharmaceuticals
Oct 23, 2025
Downgrades: Market Perform
Price Target: $19
Current: $21.42
Upside: -13.63%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Outperform
Price Target: $34
Current: $19.70
Upside: +72.59%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $11.13
Upside: +349.24%
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $11.92
Upside: -16.11%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $147.00
Upside: +2.04%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $4.15
Upside: -75.90%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $17.07
Upside: +87.46%
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $154.54
Upside: -83.82%
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $16.77
Upside: +198.15%
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $7.18
Upside: +178.55%
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $141.84
Upside: -18.92%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $169.91
Upside: +82.45%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $43.23
Upside: +6.41%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $26.60
Upside: -21.05%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $166.00
Upside: +26.51%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.95
Upside: +238.98%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $27.81
Upside: -2.91%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $5.01
Upside: +199.40%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $594.01
Upside: -54.55%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $222.82
Upside: -56.92%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $53.33
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $100.69
Upside: -33.46%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $13.31
Upside: +636.29%